“SensiQ Technologies has received Phase I funding from the National Institutes of Health to develop a next generation surface plasmon resonance-based platform,” said David Goad, PhD, Research Scientist for SensiQ Technologies and Principal Investigator for the research. “We anticipate this project will result in new, state-of-the-art SPR biosensing technology with applications in a number of research areas such as drug discovery, particularly fragment-based screening methods.” SensiQ Technologies is expected to receive approximately $1.3 Million in total funding through Phase I and Phase II of the NIH FastTrack award program.

“Coupled with our unique injection technologies known as diSPRTM, SensiQ Technologies will advance the state of the art in label-free drug discovery platforms”, said Tom Jobe, Chief Operating Officer.

Research reported in this press release was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, under award number R44TR000618.